This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
The delivery of precise doses of THC via an inhaler is associated with pain mitigation in patients with neuropathy and other complex pain conditions, according to clinicaltrial data published in the European Journal of Pain. Additional information regarding cannabinoids and pain appears online h ere.
Trauma patients administered oral THC consume fewer opioids than do similarly matched controls, according to clinicaltrial data published in the journal Trauma Surgery & Acute Care. Additional information on the relationship between cannabis and opioids is available in the NORML fact-sheet here.
According to state-registry records, “Chronic pain is currently and historically the most common qualifying condition reported by medical cannabis patients (67.5 ” This finding is hardly a surprise, as cannabis is well-established to mitigate pain in clinical models, particularly in patients with neuropathy.
There is an absence of clinical data supporting the efficacy of CBD as an antiviral agent, according to a systematic literature review published in the journal Cannabis and Cannabinoid Research. However, this data was based solely on preclinical findings.
The majority of people who use the cannabinoid cannabigerol (CBG) for medical reasons find it to be helpful or very helpful in treating a variety of health conditions, according to the findings of a recent survey. No clinicaltrial was used in the compilation of the study. Why is CBG ‘the mother of all cannabinoids?’.
As medical cannabis emerges from the dark days of prohibition, researchers are finding a wide range of conditions responding successfully to it. clinical research is extremely difficult to conduct. Epilepsy Seizure disorders are on the list of qualifying conditions for most medical cannabis states. References Staff, T.
Seventy-five percent of military veterans say that they would consider using either “cannabis or cannabinoid products as a treatment option,” according to member survey data compiled by the group Iraq and Afghanistan Veterans of America (IAVA). The organization represents over 400,000 veterans nationwide.
IGC”) (NYSE American: IGC) announces today that it has completed Cohort 2 of its Phase 1 clinicaltrial on IGC’s tetrahydrocannabinol (“THC”)-based investigational new drug, IGC-AD1, intended to alleviate the symptoms of individuals suffering from Alzheimer’s disease. This Phase 1 trial is currently testing IGC-AD1 for safety.
There is a growing body of anecdotal and scientific evidence that the “major cannabinoids” tetrahydrocannabinol (THC) and cannabidiol (CBD), certain “minor cannabinoids” (some without a name), and other cannabis compounds have antineoplastic action against cancer cells. THC binds to two types of cannabinoid receptors, CB1 and CB2.
InMed and CHDR are currently preparing the ClinicalTrial Application for a second Phase 1 clinicaltrial (755-102-HV), planned to begin in the second quarter of 2020, which will examine the local safety of INM-755 on small areas of wounded skin in healthy volunteers. For more information, visit www.inmedpharma.com.
Goldstein will be leading the Medical Practicum at CannMed 2023 (May 15-17), where she will also be speaking about CBG and other minor cannabinoids during the main session. You have said that cannabigerol, or CBG, is one of your favorite cannabinoids. Is that because CBG is a precursor for the other plant cannabinoids?
As the medical community delves into the therapeutic potential of cannabis, certain health conditions have emerged as primary candidates for its prescription. Cannabinoids, the active compounds in marijuana, interact with the endocannabinoid system in the body, modulating pain perception and inflammation.
Additionally, the NCI recognizes that cannabinoids “may have benefits in the treatment of cancer-related side effects.”. Cannabinoids are extracted from the cannabis plant and an extract oil is created. It is important to speak with a medical marijuana physician to determine which method will work best with your medical condition.
This article delves into the science behind medical marijuana, focusing on cannabinoids, the active compounds found in the cannabis plant, and their remarkable therapeutic effects. We’ll explore the diverse range of cannabinoids and their health benefits, providing insights into how these compounds are revolutionizing healthcare.
Individuals who use cannabis-based medications often want to cure their cancer, not just reduce the symptoms that come with the condition. Even if a cannabinoid has shown promise on one cancer line, that doesn’t mean it will work for all cancers – even if it’s within the same organ system. 1 So can cannabis cure cancer?
CBN is a popular cannabinoid, but what should we know about CBN and sleep? This minor cannabinoid has always existed in the cannabis plant in small quantities, but it is gaining in popularity for its potential healing properties. Unlike some other cannabinoids, it is not present in substantial amounts in fresh cannabis flower.
The 29th annual International Cannabinoid Research Society ( ICRS ) symposium, which convened last month in Bethesda, Maryland, featured new developments in CBD science that have far-reaching implications for many areas of medicine. None of the participants had been using any cannabinoid-based products prior to this study.
The endocannabinoid system consists of cannabinoid receptors all over the body. When the body is defensive against trauma or illness, this system begins to fail, resulting in physical, mental and/or neurological conditions. Cannabis offers significant therapeutic benefits for a wide range of medical conditions.
The use of cannabinoids in the treatment of medical conditions offers major opportunities and challenges to anyone operating in the space. Prohibition Partners has identified at least 30 late-stage clinicaltrials using cannabinoid therapeutics, any of which will probably have a large impact on the medicinal cannabis space.
Instead, it is hypothesised that SalA indirectly influences the cannabinoid system, as well as being an allosteric modulator of the µ opioid receptor. Clinically, there are published reports of the potential benefits of Salvia divinorum in the treatment of TRD.
So much attention is placed upon THC and CBD that sometimes the less abundant cannabinoids are forgotten about or not appreciated fully. Yet cannabinol (CBN), the first cannabinoid ever discovered by modern scientists, is slowly making a comeback in the cannabis industry. . What can the current clinicaltrials tell us?
Top 6 ways that Medical Marijuana helps patients with PTSD or other anxiety and mood disorders: Anxiety and Fear Reduction: THC (tetrahydrocannabinol) and CBD (cannabidiol) are the primary cannabinoids in cannabis that interact with the body’s own endocannabinoid system , which plays a role in regulating mood, fear, and stress responses.
The 29th annual International Cannabinoid Research Society ( ICRS ) symposium, which convened last month in Bethesda, Maryland, featured new developments in CBD science that have far-reaching implications for many areas of medicine. None of the participants had been using any cannabinoid-based products prior to this study.
We conclude that phytocannabinoids can be a low-cost and well-tolerated therapy for symptom relief and quality of life improvement in these patients, and we suggest that this therapy could be included as an herbal medicine option for the treatment of this condition in the Brazilian public health system.”. mg/mL of THC and 0.51
Living with chronic conditions such as Multiple Sclerosis (MS) is profoundly challenging and impacts various aspects of daily life. In this article, we explore how medical marijuana for multiple sclerosis symptoms helps patients, with its diverse cannabinoid components, alleviate MS symptoms, and enhance the quality of life for patients.
Florida medical marijuana doctors are recommending medical marijuana for anxiety, depression and many other mental health conditions. Anxiety is one aspect of a broader condition- anxiety disorder. The authors conclude that: Mental health conditions are prominent among the reasons for medical cannabis use. Finnell and Laurie K.
As medical cannabis emerges from the dark days of prohibition, researchers are finding a wide range of conditions responding successfully to it. clinical research is extremely difficult to conduct. Epilepsy Seizure disorders are on the list of qualifying conditions for most medical cannabis states. References Staff, T.
Ulcerative Colitis is a condition that causes long-lasting inflammation and ulcers (sores) in the innermost lining of the individual’s large intestine and rectum. Crohn’s Disease is also a condition that causes inflammation, but it affects the lining of the digestive tract, which can then spread deeply into the affected tissues. .
#image_title Families affected by Huntington’s Disease (HD) know to well that this hereditary neurodegenerative condition progressively impacts movement, cognition, and behavior, profoundly affecting both patients and their loved ones. “Every patient I see brings more than just their symptoms.”
. (“InMed” or the “Company”) (TSX: IN; OTCQX: IMLFF), today announced the filing of a ClinicalTrial Application (“CTA”) in the Netherlands to initiate a Phase 1 human clinicaltrial for INM-755 in healthy volunteers. For more information, visit www.inmedpharma.com. About INM-755.
. (“InMed” or the “Company”) (TSX: IN; OTCQX: IMLFF), today announced the filing of a ClinicalTrial Application (“CTA”) in the Netherlands to initiate a Phase 1 human clinicaltrial for INM-755 in healthy volunteers. For more information, visit www.inmedpharma.com. About INM-755.
Cannabis has been shown to be an effective treatment for a variety of conditions caused by bacteria, viruses and fungi. This is because it contains cannabinoids, which have anti-inflammatory properties. Many neurological conditions are associated with dysregulation of the ECS (for example: epilepsy, Parkinson’s disease).
IGC” or the “Company”) today announced positive primary endpoint data for its Phase 1 clinicaltrial for IGC-AD1, which is a proprietary cannabinoid-based investigational new drug candidate for patients who have Alzheimer’s disease. The trial was conducted as a multiple ascending dose (MAD) study.
Post-Traumatic Stress Disorder (PTSD) is a multifaceted mental health condition triggered by experiencing or witnessing traumatic events, persistently manifesting in symptoms like flashbacks, severe anxiety, and disrupted sleep. Research suggests that cannabinoids may modulate these processes, potentially offering relief from PTSD symptoms.
It’s well known that marijuana can be an agent for appetite stimulation, making it a valuable therapy for mitigating the weight loss sometimes associated with conditions such as HIV/AIDS and cancer. The condition can lead to weight gain and obesity. Binges are often followed by feelings of guilt and shame.
It seems like the medical research community remains largely divided on the issue, with some insisting that cannabis use contributes to mental health condition diagnoses while others suggesting that people with mental health conditions are inherently drawn to cannabis use.
Any future research or clinicaltrials targeting the efficacy of cannabis should clearly define these recommendations for use and prioritize the communication of such recommendations to enrolled participants,” they added. The post Why more Parkinson’s patients don’t use cannabis appeared first on The Cannigma.
InMed and CHDR are currently preparing the ClinicalTrial Application for a second Phase 1 clinicaltrial (755-102-HV), planned to begin in the second quarter of 2020, which will examine the local safety of INM-755 on small areas of wounded skin in healthy volunteers. For more information, visit www.inmedpharma.com.
Cannabinoids are a class of chemical compounds found in the cannabis plant. There are over 100 cannabinoids, and they are responsible for the plant’s therapeutic effects. Cannabinoids interact with our body’s endocannabinoid system, which regulates many important functions, including mood, appetite, and pain.
In recent years, research has revealed that two of marijuana’s two major cannabinoids — THC and CBD — can interact with the human endocannabinoid system to influence bone healing and regeneration. THC, CBD & THE ECS. THC, CBD & THE ECS. In their summary, the study’s authors noted that. MARIJUANA AND OSTEOPOROSIS.
CBD, which is an abbreviation for Cannabidiol, is one of Cannabis’s primary components – one of its primary Cannabinoids. Cannabinoids are the naturally occurring compounds found in the Cannabis plant. There are over 480 different Cannabinoids in the Cannabis plant. It is non-psychoactive and has a multitude of health benefits.
Alleviating Symptoms with Cannabinoids As more states legalize medical cannabis, many researchers and clinicians are studying the efficacy of cannabinoids like THC and CBD for alleviating these symptoms. One study from the Journal of Clinical Oncology examined the efficacy of cannabinoids in appetite stimulation.
CBN has made headlines and claimed shelf space as the next best cannabinoid for sleep. While CBN is often marketed as “the sleep cannabinoid ,” the reality is more complicated. Sleep is not often the focus of clinicaltrials on cannabis; rather it is often a secondary outcome. Has CBN been proven to help with sleep?
(IGC) is excited to present preliminary positive secondary end point findings from its Phase 1 clinicaltrial for IGC-AD1. The results of the clinicaltrial have been submitted in the Clinical/Statistical Report (“CSR”) filed with the FDA, and relevant data is also available on Form 8-K filed with the SEC on December 2, 2021.
We organize all of the trending information in your field so you don't have to. Join 14,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content